Hantz Financial Services, Inc. Ascendis Pharma A/S Transaction History
Hantz Financial Services, Inc.
- $6.6 Billion
- Q3 2025
A detailed history of Hantz Financial Services, Inc. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 844 shares of ASND stock, worth $172,513. This represents 0.0% of its overall portfolio holdings.
Number of Shares
844
Previous 352
139.77%
Holding current value
$172,513
Previous $61,000
175.41%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ASND
# of Institutions
316Shares Held
65.1MCall Options Held
476KPut Options Held
142K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.1 Billion35.1% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...